Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average PT from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been assigned an average rating of “Buy” from the five research firms that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $12.38.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Alpine Global Management LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth about $62,000. Squarepoint Ops LLC grew its holdings in Corvus Pharmaceuticals by 712.5% during the 4th quarter. Squarepoint Ops LLC now owns 98,144 shares of the company’s stock worth $525,000 after acquiring an additional 86,064 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth about $2,678,000. RTW Investments LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth about $14,335,000. Finally, Man Group plc bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth about $73,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS stock opened at $4.31 on Tuesday. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The stock has a market cap of $276.95 million, a price-to-earnings ratio of -4.63 and a beta of 0.91. The firm has a fifty day moving average of $4.74 and a 200-day moving average of $6.08.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.